Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REZAFECT
2024-519789-37-00Phase 4Authorised
- Sponsor
- Medical University of Graz
- Start
- Apr 2025
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rezafungin in invasive candidiasis and invasive mycoses (2 arms), sponsored by Medical University of Graz. Primary endpoints: Clearance (CL), Volume of distribution (Vd) and 7 more. Planned start Apr 2025; status: authorised.
02
Drugs
rezafungin
03
Conditions
invasive candidiasisinvasive mycoses
Beyond the preview
Go deeper on 2024-519789-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519789-37-00.